"Designing Growth Strategies is in our DNA"

Granulomatosis With Polyangiitis Treatment Market Size, Share and Global Trend By Drug Class (Steroids, Immunosuppressant), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Regional Forecast, 2024-2032

Region : Global | Report ID: FBI100209 | Status : Ongoing



Granulomatosis With Polyangiitis, also previously referred to as Wegener's granulomatosis is a rarer form of the autoimmune disease known as vasculitis. In this disorder, the smaller sized blood vessels of lungs, kidneys, nose, sinuses, and ears become inflamed, which leads to the damage to these organs and parts of the body. According to the National Institutes of Health (NIH), granulomatosis with polyangiitis affects an estimated 3 per 100,000 individuals’ in the U.S.

In October 2018, the Food and Drug Administration (FDA) approved the update of the label, to include the follow up treatment of adult patients with Genentech’s product offering of Rituxan (Rituximab) for the treatment of two rarer forms of vasculitis: Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), after their administration showed disease control. Rituxan, in combination with corticosteroids, is the only FDA approved therapy for this rare, life-threatening disease affecting the blood vessels.

To gain extensive insights into the market, Request for Customization


Due to the regulatory approval of the combination therapy of Rituxan (Rituximab) and the corticosteroids and the greater awareness of the disease in the developed and the developing markets positively driving the market growth considerably. The further advances of the R&D and the life-threatening nature of the disease is also contributing positively to the market growth. 

The factor that is expected to inhibit the growth of the market is the associated side effects of the treatment options such as the medication toxicity and the adverse effects of corticosteroids. Regulatory and clinical hurdles might also impact the growth of the market due to delays in product approvals, which might limit the launches of new products. 

Key Players Covered 

Some of the major companies that are present in the global Granulomatosis with Polyangiitis Treatment market Genentech, Inc., GlaxoSmithKline plc., Sonoma Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Antares Pharma, Medac Pharma, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Pfizer Inc. 





By Drug Class

·      Steroids

·      Immunosuppressant

·      Others

By Route of Administration

·      Oral

·      Intravenous

·      Others

By Distribution Channel

·      Hospital Pharmacies

·      Retail Pharmacies

·      Others

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


At present, steroids account for the largest proportion of the market and this is not expected to change in the forecast period based on the regulatory scenario. This is because of the only regulatory approved treatment option is of corticosteroids combined with the Rituxan. 

Key Insights 

  • Epidemiology overview: incidence of granulomatosis with polyangiitis, by key countries/regions
  • Treatment guidelines for management of remission and refractory granulomatosis with polyangiitis
  • Overview: alternative treatments for granulomatosis with polyangiitis
  • Proportion (%) of patients suffering from granulomatosis with polyangiitis undergoing alternative treatments
  • Overview of clinical trials: granulomatosis with polyangiitis 

Regional Analysis 

The global Granulomatosis with Polyangiitis Treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for Granulomatosis with Polyangiitis Treatment at present and they are expected to account for a large proportion of the market in the forecast period as well. The first U.S. FDA approval for the treatment of Granulomatosis with Polyangiitis was Rituxan in combination with corticosteroids, which was approved by the FDA in the U.S. in 2011 and the further label update was approved in 2018. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This is because Japan and China has the comparatively highest prevalence of the disease and also the diagnostic capacities. 

Key Industry Developments

  • In October 2018, the FDA approved the update to the label of the treatment of Granulomatosis with Polyangiitis, for the combination therapy of corticosteroids and Rituxan.
  • InflaRx GmbH along with IQVIA are undertaking a clinical trial of a molecular entity named IFX-1 as an add-on to the standard of care for the patients with Granulomatosis with Polyangiitis (GPA), as compared with placebo. This trial is in the Phase 2 of the clinical trials stage.

  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients


Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.